Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-007 in resectable locally advanced cutaneous squamous cell carcinoma
MOH_2024-03-14_013173Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of intismeran autogene and pembrolizumab in cutaneous squamous cell carcinoma (cSCC) (3 arms), sponsored by Merck & Co. Started Jan 2024; status: active, not recruiting.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on MOH_2024-03-14_013173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-14_013173.